NASDAQ · PALI
Palisade Bio, Inc.
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
Loading market information…
OTC · CASIF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CASI Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CASI Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.35. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CASI Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. The company's offerings include EVOMELA, an intravenous formulation of melphalan, which serves as a conditioning treatment before stem cell transplantation and as palliative care for patients with multiple myeloma. Its hematology/oncology pipeline is robust, featuring CNCT19, an investigative autologous CD19 CAR-T product; BI-1206, a novel anti-FcγRIIB antibody designed for treating solid tumors and relapsed/refractory non-Hodgkin lymphoma; CB-5339, an innovative VCP/p97 inhibitor targeting valosin-containing protein (VCP)/p97 pathways crucial for protein homeostasis, DNA damage response, and cellular stress in various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent with diverse indications, including its use as a conditioning regimen prior to certain allogeneic hematopoietic stem cell transplants. CASI Pharmaceuticals maintains licensing agreements with entities such as Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C., primarily for the development and commercialization of its commercial product, EVOMELA. The company was founded in 1991 and is headquartered in Beijing, People's Republic of China.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:14 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 16, 2025 |
| -$0.69-13.11% vs estimate |
| $6.24M-0.95% vs estimate |
| Q4 2024 | Mar 31, 2025 | -$0.79-31.67% vs estimate | $13.36M+80.63% vs estimate |
|---|
| Q3 2024 | Nov 15, 2024 | -$0.55+11.29% vs estimate | $7.79M+70.9% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
$16.54+$0.80 (+5.08%)
Pelthos Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.89% below the high.
$0.89-$0.06 (-6.32%)
Allarity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.63% below the high.
$2.85-$0.15 (-5.0%)
Entero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.2% below the high.
$1.01-$0.05 (-4.72%)
Lisata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.08% below the high.
$1.04-$0.04 (-3.26%)
NuCana plc’s quoted price sits in the lower half of its reported 52-week range, 77.14% below the high.
$0.41$0.00 (0.0%)
Clearside Biomedical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.6% below the high.
